Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBOAT4 | Q96T53 | 4/20 | 0.75 |
| ▸ | NOS2 | P35228 | 9/20 | 0.58 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.58 |
| ▸ | USP7 | Q93009 | 2/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | STAT3 | P40763 | 1/20 | 0.58 |
| ▸ | RORC | P51449 | 1/20 | 0.51 |
| ▸ | CCR6 | P51684 | 1/20 | 0.51 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12447445 | 0.91 | MBOAT4 (0.62) | MBOAT4NOS2KEAP1CYP3A4CYP2C9 | |
| SCHEMBL83431 | 0.91 | MBOAT4 (0.62) | MBOAT4NOS2KEAP1CYP3A4CYP2C9 | |
| SCHEMBL83432 | 0.91 | MBOAT4 (0.76) | MBOAT4NOS2KEAP1CYP3A4CYP2C9 | |
| SCHEMBL12447444 | 0.89 | NFE2L2 (0.62) | MBOAT4NOS2KEAP1CYP3A4CYP2C9 | |
| SCHEMBL82945 | 0.88 | NOS2 (0.73) | MBOAT4NOS2KEAP1CYP3A4CYP2C9 | |
| SCHEMBL12447479 | 0.88 | CYP3A4 (0.73) | MBOAT4NOS2KEAP1CYP3A4CYP2C9 | |
| SCHEMBL13393866 | 0.88 | CYP3A4 (0.73) | MBOAT4NOS2KEAP1CYP3A4CYP2C9 | |
| SCHEMBL82937 | 0.88 | CYP3A4 (0.73) | MBOAT4NOS2KEAP1CYP3A4CYP2C9 | |
| SCHEMBL12136833 | 0.88 | NOS2 (0.73) | MBOAT4NOS2KEAP1CYP3A4CYP2C9 | |
| SCHEMBL12200189 | 0.88 | MBOAT4 (0.59) | MBOAT4NOS2KEAP1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911395-B2 | Methods of treating obesity using antioxidant inflammation modulators | Reata Pharmaceuticals Holdings, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230285500-A1 | Compositions and Methods for Gene Therapy for Corneal Endothelium Disorders | THE SCHEPENS EYE RESEARCH INSTITUTE, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20180161311-A1 | SYNTHETIC TRITERPENOIDS AND METHODS OF USE IN THE TREATMENT OF DISEASE | REATA PHARMACEUTICALS, INC. (US) | 2018-06-14 | — | — | US | disclosed |
| US-20170333450-A1 | COMPOSITIONS AND METHODS FOR TREATING HIV-ASSOCIATED COGNITIVE DYSFUNCTION | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2017-11-23 | — | — | US | disclosed |
| US-9757359-B2 | Synthetic triterpenoids and methods of use in the treatment of disease | REATA PHARMACEUTICALS, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-20160175380-A1 | Compositions and Methods of Treatment of Corneal Endothelium Disorders | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2016-06-23 | — | — | US | disclosed |
| US-20150080465-A1 | METHODS OF TREATING AND PREVENTING ENDOTHELIAL DYSFUNCTION USING BARDOXOLONE METHYL OR ANALOGS THEREOF | REATA PHARMACEUTICALS, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-20140328809-A1 | METHODS OF INDUCING CHONDROGENESIS IN MESENCHYMAL STEM CELLS USING SYNTHETIC TRITERPENOIDS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR NIH | 2014-11-06 | — | — | US | disclosed |
| US-8778990-B2 | Betulinic acid derivatives and methods of use thereof | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130288985-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF CORNEAL ENDOTHELIUM DISORDERS | THE SCHEPENS EYE RESEARCH INSTITUTE INC. (US) | 2013-10-31 | — | — | US | disclosed |
| US-8455544-B2 | Synthetic triterpenoids and methods of use in the treatment of disease | Reata Pharmaecuticals, Inc. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20120220652-A1 | Synthetic Triterpenoids and Methods of Use in the Treatment of Disease | REATA PHARMACEUTICALS, INC. | 2012-08-30 | — | — | US | disclosed |
| US-20120101149-A1 | Betulinic Acid Derivatives and Methods of Use Thereof | REATA PHARMACEUTICALS, INC. | 2012-04-26 | — | — | US | disclosed |
| US-8129429-B2 | Synthetic triterpenoids and methods of use in the treatment of disease | REATA PHARMACEUTICALS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20110281955-A1 | METHODS OF TREATING OBESITY USING ANTIOXIDANT INFLAMMATION MODULATORS | REATA PHARMACEUTICALS (US) | 2011-11-17 | — | — | US | disclosed |
| US-20090326063-A1 | SYNTHETIC TRITERPENOIDS AND METHODS OF USE IN THE TREATMENT OF DISEASE | REATA PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090048205-A1 | COMBINATION THERAPY WITH SYNTHETIC TRITERPENOIDS AND GEMCITABINE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160175380-A1 | Compositions and Methods of Treatment of Corneal Endothelium Disorders | FECH, KEAP1, NFE2L2 | MBOAT4 4178/4885NOS2 366/4885KEAP1 2/4885 |
| US-20130288985-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF CORNEAL ENDOTHELIUM DISORDERS | FECH, KEAP1, NFE2L2 | MBOAT4 4178/4885NOS2 366/4885KEAP1 2/4885 |
| US-20170333450-A1 | COMPOSITIONS AND METHODS FOR TREATING HIV-ASSOCIATED COGNITIVE DYSFUNCTION | CD14, CCL2, CCR5 | MBOAT4 3418/4885NOS2 14/4885KEAP1 107/4885 |
| US-11911395-B2 | Methods of treating obesity using antioxidant inflammation modulators | TXNRD2, HMOX1, GPX4 | MBOAT4 92/4885NOS2 83/4885KEAP1 60/4885 |
| US-20090326063-A1 | SYNTHETIC TRITERPENOIDS AND METHODS OF USE IN THE TREATMENT OF DISEASE | LIPG, CYP27A1, CYP11B1 | MBOAT4 1458/4885NOS2 378/4885KEAP1 444/4885 |
| US-20180161311-A1 | SYNTHETIC TRITERPENOIDS AND METHODS OF USE IN THE TREATMENT OF DISEASE | LIPG, CYP27A1, CYP11B1 | MBOAT4 1458/4885NOS2 378/4885KEAP1 444/4885 |
| US-20090048205-A1 | COMBINATION THERAPY WITH SYNTHETIC TRITERPENOIDS AND GEMCITABINE | RABGGTB, BAD, PGGT1B | MBOAT4 1132/4885NOS2 3154/4885KEAP1 1567/4885 |
| US-20120220652-A1 | Synthetic Triterpenoids and Methods of Use in the Treatment of Disease | LIPG, CYP27A1, CYP11B1 | MBOAT4 1458/4885NOS2 378/4885KEAP1 444/4885 |
| US-20140328809-A1 | METHODS OF INDUCING CHONDROGENESIS IN MESENCHYMAL STEM CELLS USING SYNTHETIC TRITERPENOIDS | BMP2, BMP4, EBP | MBOAT4 2120/4885NOS2 876/4885KEAP1 702/4885 |
| US-20110281955-A1 | METHODS OF TREATING OBESITY USING ANTIOXIDANT INFLAMMATION MODULATORS | TXNRD2, HMOX1, GPX4 | MBOAT4 92/4885NOS2 83/4885KEAP1 60/4885 |
| US-20120101149-A1 | Betulinic Acid Derivatives and Methods of Use Thereof | BET1, PGGT1B, CYP3A5 | MBOAT4 3063/4885NOS2 1733/4885KEAP1 307/4885 |
| US-20150080465-A1 | METHODS OF TREATING AND PREVENTING ENDOTHELIAL DYSFUNCTION USING BARDOXOLONE METHYL OR ANALOGS THEREOF | EDNRA, EDNRB, CYP11B1 | MBOAT4 1348/4885NOS2 40/4885KEAP1 53/4885 |
| US-20230285500-A1 | Compositions and Methods for Gene Therapy for Corneal Endothelium Disorders | KEAP1, NFE2L2, TFAM | MBOAT4 3834/4885NOS2 540/4885KEAP1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.